Greater Bay Area Planning | Dr. H. Fai Poon, CEO of QuaCell Biotechnology, was invited to share the cooperation policy recommendations of the Association for Science and Technology
May 11, 2021
In August 2020, the Hong Kong Association for Science and Technology, Director Xue and Deputy Director Zhong of the Hong Kong Innovation and Technology Bureau conducted a discussion on why Zhongshan was chosen as the pilot for the start-up park. Dr.H. Fai Poon, CEO of QuaCell Biotechnology, was invited to participate in the sharing.
BioInno and QuaCell Biotechnology reached a strategic cooperation on the CHO-K1Q Host Cell Platform
May 11, 2021
Suzhou BioInno Bioscience Co., Ltd. (hereinafter referred to as "BioInno Bioscience") and Zhongshan QuaCell Biotechnology Co., Ltd. (hereinafter referred to as "QuaCell Biotechnology") jointly announced that the two parties will reach a strategic cooperation intention on the introduction of the CHO-K1Q host cell platform and the cooperation of CDMO service projects.
QuaCell® Serum-Free Cell Cryopreservation Solution Obtained the First Class Medical Device Recording Certificate
May 11, 2021
On October 28, 2020, Zhongshan City Market Supervision and Administration Bureau issued the first-class medical device registration certificate to our company for QuaCell® Serum-free Cell Cryopreservation Solution (Cat. No.: B31001).
The Mayor of Zhongshan Wei Hanwei visited QuaCell Biotechnology
May 11, 2021
On December 9, 2020, the mayor of Zhongshan Weiweihan and his entourage visited QuaCell Biotechnology, Co., Ltd. (hereinafter referred to as "QuaCell") for investigation and tour guidance.
Dr H.Fai Poon was invited to participate in the 2020 Hong Kong Entrepreneur Youth Mainland Trip
May 11, 2021
Dr H.Fai Poon, CEO of QuaCell Biotechnology, was invited to participate in the 2020 Hong Kong Entrepreneur Youth Mainland Tour and Greater Bay Area Entrepreneur Youth Online Exchange to share his entrepreneurial journey.
Dr. H.Fai Poon participated in the Guangzhou Biomedical Innovation R&D Forum
May 11, 2021
On December 19, 2020, Dr. H.Fai Poon, CEO of QuaCell Biotechnology, Co., Ltd. (hereinafter referred to as "QuaCell"), was invited to participate in Guangzhou Biomedical Innovation and R&D Forum of the 2020 International Trade Fair.
QuaCell Biotechnology completes a new round of financing｜Introduction of our Strategic Investor Shenzhen Capital Group CO., LTD.
May 11, 2021
QuaCell Biotechnology, Co., Ltd. (hereinafter referred to as "QuaCell"), announced the completion of a new round of financing and the introduction of strategic investor Shenzhen Innovation Investment Group Co., Ltd. ("Shenzhen Venture Capital").
OBiO and QuaCell Biotechnology reached a strategic cooperation on the joint development of the Wayne293™ host cell platform and high-toxin-producing derivative cell lines
May 11, 2021
On March 9, 2021, OBiO and QuaCell Biotechnology jointly announced a strategic cooperation intent on the joint development of the Wayne293™ host cell platform and high-toxin-producing derivative cell lines. This cooperation aims to complement each other's technological advantages, connect upstream and downstream, and provide more comprehensive, high-quality and efficient technical services and solutions to cell and gene therapy customers around the world.
China Medical System company(CMS) visited Quacell Biotechnology
May 11, 2021
Mr Lin Gang, Chairman of the Board of Directors of CMS Co., Ltd., Mr Wang Gang, General Manager of CMS Health Fund, and Mr Zhou Haiyang, Deputy General Manager, visited QuaCell Biotechnology Co., Ltd. (Quacell Biotechnology) and for investigation.
Quacell Biotechnology and India Samas reached a CRO service cooperation
May 10, 2021
Two sides will conduct comprehensive cooperation on host cell lines, culture media, CRO services and other aspects in the six monoclonal antibody projects. Samarth Group, founded in 1963, is one of the top ten pharmaceutical groups in India.